The Niche Episode 038 – Amgen, Five Prime, KemPharm, Colfax

Amgen nabs Five Prime Therapeutics in $1.9B deal, KemPharm ligates their way out of debt with ADHD, three failed COVID19 pipelines, and Colfax follows 2019 merger with corporate split.

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/niche-038-1
https://tinyurl.com/niche-038-2
https://tinyurl.com/niche-038-3
https://tinyurl.com/niche-038-4

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

THIS CONTENT IS FOR

Registered Users

Please login or register to continue.